abstract: A retrospective review was carried out to study @entity0 , not more than 16 years old, with a confirmed diagnosis of @entity4 , who were residents of the Province of Ontario at the time of diagnosis between 1977 and 1987 inclusive. The provincial @entity1 registry provided the population database. One hundred and eight @entity0 with @entity4 were identified of whom 72 (67%) were initially treated at University of Toronto Centres and 36 (33%) at other Health Science Centres, hospitals, and @entity1 ( @entity1 ) in Ontario. The hospital/ @entity1 Centre records were reviewed. The 5-year relapse-free survival (RFS) for all @entity0 treated in Ontario was 58% (SE = 5%). Those treated in Toronto had a 5-year RFS of 65% (SE = 6%) compared to 44% (SE = 8%) for those treated in other RCCs in the province (P = 0.02). Relapse-free survival for the RCCs ranged from 25 to 60%, with a trend for improved survival with increasing centre size. Univariate analysis of determinants of relapse-free survival for all 108 @entity0 showed the following variables to be significant: T-stage (Tx + T1 + T2 vs. @entity5 + T3B) P = 0.0004, M-stage (M0 + Mx vs. M1-4) P = 0.0006, extent of resection (total vs. less than total) P = 0.002, radiotherapy (craniospinal irradiation and posterior fossa boost vs. other) P = 0.02, and treatment centre (Toronto centres vs. @entity1 ) P = 0.02. Cases treated at centres outside metropolitan Toronto had a nearly two-fold (relative risk = 1.93; 95% confidence interval = 1.07, 3.47) greater risk of recurrence or @entity2 than those seen in Toronto. However, in multivariate analysis this difference was not quite significant (P = 0.07) after controlling for stage (T and M), extent of resection, @entity3 , and gender. These data suggest that @entity0 with @entity4 should be referred for treatment to large centres with major pediatric neurosurgical and oncology resources.

title: XXXX in Ontario, 1977-1987: population-based results.

answer: @entity4


abstract: One hundred and fifty-nine @entity0 with @entity2 were assessed with Rigiscan monitoring of nocturnal penile tumescence (NPT) and response to intracavernosal injections (ICI) of @entity5 or @entity6 . A satisfactory NPT, suggestive of psychogenic causation, was recorded in 58%, whereas 15% had clearly impaired NPT. There was a significant association between presence of @entity3 , @entity1 and @entity4 . For ICI, only 32% showed a satisfactory response, with 48% clearly impaired. Of the 92 @entity0 with satisfactory NPT, 40% HAD clearly impaired and 41% satisfactory ICI response. Of the 51 @entity0 with satisfactory ICI response, 8% had clearly impaired and 74.5% satisfactory NPT. There was no association between ICI response and history of @entity3 . We conclude that monitoring of NPT by Rigiscan, and without sleep monitoring, is a valuable diagnostic procedure. In contrast, because of the high proportion of false negative results. ICI monitoring is of very limited diagnostic value. The explanation for false negative ICI responses, however, could prove to be of considerable theoretical and clinical importance.

title: The clinical assessment of XXXX : a comparison of nocturnal penile tumescence monitoring and intracavernosal injections.

answer: @entity2


abstract: PURPOSE: @entity2 recurrence is a rare but serious complication in @entity0 with @entity4 , leading to a high risk of @entity1 and @entity3 . Therefore, we assume that these recurrences have to be detected and treated as early as possible. Preliminary studies used magnetic resonance imaging (MRI) to evaluate postsurgical findings in the orbit. In this study, we assessed the diagnostic accuracy of high-resolution MRI to detect @entity2 recurrence in @entity0 with @entity4 in a large study cohort. DESIGN: Consecutive retrospective study (2007-2013) assessing MRI findings after enucleation. @entity0 : A total of 103 MRI examinations of 55 orbits (50 @entity0 , 27 male/23 female, mean age 16.3  12.4 months) with a median time of 8 months (range, 0-93) after enucleation for @entity4 . METHODS: High-resolution MRI using orbital surface coils was performed on 1.5 Tesla MRI systems to assess abnormal orbital findings. MAIN OUTCOME MEASURES: Five European experts in @entity4 imaging evaluated the MRI examinations regarding the presence of abnormal orbital @entity5 enhancement and judged them as " @entity2 ," "suspicious of @entity2 ," "postsurgical condition/scar formation," or "without pathologic findings." The findings were correlated to histopathology (if available), MRI, and clinical follow-up. RESULTS: Abnormal orbital enhancement was a common finding after enucleation (100% in the first 3 months after enucleation, 64.3% >3 years after enucleation). All histopathologically confirmed @entity2 recurrences (3 of 55 orbits, 5.5%) were correctly judged as " @entity2 " in MRI. Two orbits from 2 @entity0 rated as "suspicious of @entity2 " received intravenous chemotherapy without histopathologic confirmation; further follow-up (67  and 47 months) revealed no sign of @entity2 recurrence. In 90.2%, no @entity2 was suspected on MRI, which was clinically confirmed during follow-up (median follow-up after enucleation, 45 months; range, 8-126). CONCLUSIONS: High-resolution MRI with orbital surface coils may reliably distinguish between common postsurgical contrast enhancement and @entity2 recurrence, and therefore may be a useful tool to evaluate @entity2 recurrence after enucleation in @entity0 with @entity4 . We recommend high-resolution MRI as a potential screening tool for the orbit in @entity0 with @entity4 to exclude @entity2 recurrence, especially in high-risk @entity0 within the critical first 2 years after enucleation.

title: High-Resolution Magnetic Resonance Imaging  Can Reliably Detect Orbital Tumor  Recurrence after Enucleation in  @entity0 with XXXX .

answer: @entity4


abstract: PURPOSE: @entity2 recurrence is a rare but serious complication in @entity0 with @entity4 , leading to a high risk of @entity1 and @entity3 . Therefore, we assume that these recurrences have to be detected and treated as early as possible. Preliminary studies used magnetic resonance imaging (MRI) to evaluate postsurgical findings in the orbit. In this study, we assessed the diagnostic accuracy of high-resolution MRI to detect @entity2 recurrence in @entity0 with @entity4 in a large study cohort. DESIGN: Consecutive retrospective study (2007-2013) assessing MRI findings after enucleation. @entity0 : A total of 103 MRI examinations of 55 orbits (50 @entity0 , 27 male/23 female, mean age 16.3  12.4 months) with a median time of 8 months (range, 0-93) after enucleation for @entity4 . METHODS: High-resolution MRI using orbital surface coils was performed on 1.5 Tesla MRI systems to assess abnormal orbital findings. MAIN OUTCOME MEASURES: Five European experts in @entity4 imaging evaluated the MRI examinations regarding the presence of abnormal orbital @entity5 enhancement and judged them as " @entity2 ," "suspicious of @entity2 ," "postsurgical condition/scar formation," or "without pathologic findings." The findings were correlated to histopathology (if available), MRI, and clinical follow-up. RESULTS: Abnormal orbital enhancement was a common finding after enucleation (100% in the first 3 months after enucleation, 64.3% >3 years after enucleation). All histopathologically confirmed @entity2 recurrences (3 of 55 orbits, 5.5%) were correctly judged as " @entity2 " in MRI. Two orbits from 2 @entity0 rated as "suspicious of @entity2 " received intravenous chemotherapy without histopathologic confirmation; further follow-up (67  and 47 months) revealed no sign of @entity2 recurrence. In 90.2%, no @entity2 was suspected on MRI, which was clinically confirmed during follow-up (median follow-up after enucleation, 45 months; range, 8-126). CONCLUSIONS: High-resolution MRI with orbital surface coils may reliably distinguish between common postsurgical contrast enhancement and @entity2 recurrence, and therefore may be a useful tool to evaluate @entity2 recurrence after enucleation in @entity0 with @entity4 . We recommend high-resolution MRI as a potential screening tool for the orbit in @entity0 with @entity4 to exclude @entity2 recurrence, especially in high-risk @entity0 within the critical first 2 years after enucleation.

title: High-Resolution Magnetic Resonance Imaging  Can Reliably Detect Orbital Tumor  Recurrence after Enucleation in  XXXX with @entity4 .

answer: @entity0


abstract: OBJECTIVES: Very few studies have investigated the incidence and risk of @entity4 ( @entity4 ) associated with distinct sources of @entity3 exposure, especially exposure to naturally occurring @entity3 (NOA). METHODS: Subjects were @entity4 , lung, and @entity0 @entity1 who were diagnosed and followed in Diyarbakir Province between 2008 and 2013. The birthplaces of @entity1 were displayed on a geologic map. Geological and meteorological effects on @entity4 were analyzed by logistic regression. RESULTS: A total of 180 @entity4 , 368 breast, and 406 @entity2 @entity1 were included. The median distance from birthplace to ophiolites was 6.26  km for @entity4 , 31.06  km for lung, and 34.31  km for @entity0 (p  <  0.001). The majority of @entity4 cases were seen within 20  km from NOA areas. The @entity4 incidence inside of NOA was 1059/100.000, and out of NOA was 397/100.000; this difference was significant (p  =  0.014). The largest concentration of @entity4 residential areas was within    30   (34 residential areas 36.6  %) of the dominant wind direction. Most @entity4 @entity1 were found in or near the dominant wind direction, especially in the acute angle defined by the dominant wind direction. @entity4 incidence was directly proportional to {[area of NOA (km(2))] * [cosine a of wind direction angle]} and was inversely proportional to the square of the distance (R  =  0.291, p  =  0.023). CONCLUSIONS: @entity4 was higher near NOA and in the downwind direction. @entity4 incidence and risk were affected by geological and meteorological factors.

title: High-risk mesothelioma relation to meteorological and geological condition and distance from naturally occurring XXXX .

answer: @entity3


abstract: Untreated essential @entity2 is associated with @entity4 ( @entity4 ) and structural changes in resistance vessels. The aim of this study was to establish the effect of @entity5 based antihypertensive therapy on media thickness to lumen diameter (media:lumen) ratio of peripheral resistance vessels and left ventricular mass in essential @entity2 . Twenty-five @entity0 with newly diagnosed or poorly regulated essential @entity2 were treated with @entity5 . Insufficient treatment response ( @entity7 > 90 mmHg) led to addition of @entity6 , and @entity3 was used as a tertiary drug if necessary. Gluteal subcutaneous biopsies were taken surgically at baseline and after 9 months of successful treatment. Two small resistance arteries were isolated and mounted in a small vessel myograph, and media:lumen ratio (%) was measured under standardized conditions. Left ventricular mass was determined by echocardiography. Mean (SD) media:lumen ratio decreased from 9.8 (2.6) % to 7.8 (1.9) % (p < 0.05), while left ventricular mass decreased from 299 (75) g to 199 (53) g (p < 0.001). Correlation was found between changes in left ventricular mass index and media:lumen ratio (r = 0.62, p < 0.01). It is concluded that a @entity5 based regimen efficiently normalizes resistance artery structure and @entity4 in essential @entity2 within one year of treatment. The impact of these findings on the excess @entity1 and mortality in @entity2 remains to be investigated.

title: Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor XXXX .

answer: @entity5


abstract: Ab externo @entity3 :YAG Holmium laser sclerostomy is an interesting alternative to standard full thickness filtering surgery. We report our retrospective experience over a total number of 38 sclerostomies between march 1993 and september 1994 on 32 @entity0 (33 eyes) with primary or secondary @entity1 composed of 17 phakic and 16 aphakic and/or @entity2 . The mean @entity0 age is 62.9 years (range: 10 to 90 years). The mean follow-up time is 7.5 months (1 to 18 months). We used a long pulsed (300 microsec) laser emitting in the near infrared (2.1 microns). A conjunctival stab incision was made 12 mm away from the sclerostomy site to allow entry of a 22 G probe which delivers energy at a right angle to the long axis of the fiber. We used 100 mJ per pulse laser energy delivered at a rate of 5 impacts per second. The mean delivered energy to produce a functional sclerostomy was 16.1 J. All @entity0 received subconjunctival injections of 5 @entity4 (mean number of injections: 7.4). Criteria for success included an IOP of 22 mmH or less with or without additional medical treatment and a decrease of at least 30% of IOP when the preoperative IOP was 22 mmHg or less. The mean preoperative IOP was 35.8 mmHg (21 to 54 mmHg). By 3 months, the mean IOP of the 14 eyes over 19 successfully controlled was 15.2 mmHg (8 to 22 mmHg) with additional medical treatment in 3 cases. By 6 months, 11 eyes over 11 successfully controlled was 14.1 mmHg (6 to 21 mmHg) with additional medical treatment in 3 cases.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [External sclerostomy using the @entity3 :YAG Holmium laser in the treatment of XXXX ].

answer: @entity1


abstract: Ab externo @entity3 :YAG Holmium laser sclerostomy is an interesting alternative to standard full thickness filtering surgery. We report our retrospective experience over a total number of 38 sclerostomies between march 1993 and september 1994 on 32 @entity0 (33 eyes) with primary or secondary @entity1 composed of 17 phakic and 16 aphakic and/or @entity2 . The mean @entity0 age is 62.9 years (range: 10 to 90 years). The mean follow-up time is 7.5 months (1 to 18 months). We used a long pulsed (300 microsec) laser emitting in the near infrared (2.1 microns). A conjunctival stab incision was made 12 mm away from the sclerostomy site to allow entry of a 22 G probe which delivers energy at a right angle to the long axis of the fiber. We used 100 mJ per pulse laser energy delivered at a rate of 5 impacts per second. The mean delivered energy to produce a functional sclerostomy was 16.1 J. All @entity0 received subconjunctival injections of 5 @entity4 (mean number of injections: 7.4). Criteria for success included an IOP of 22 mmH or less with or without additional medical treatment and a decrease of at least 30% of IOP when the preoperative IOP was 22 mmHg or less. The mean preoperative IOP was 35.8 mmHg (21 to 54 mmHg). By 3 months, the mean IOP of the 14 eyes over 19 successfully controlled was 15.2 mmHg (8 to 22 mmHg) with additional medical treatment in 3 cases. By 6 months, 11 eyes over 11 successfully controlled was 14.1 mmHg (6 to 21 mmHg) with additional medical treatment in 3 cases.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [External sclerostomy using the XXXX :YAG Holmium laser in the treatment of @entity1 ].

answer: @entity3


abstract: Reliable prognostic factors are needed to improve the stratification of @entity1 with @entity0 to different therapy modalities. We investigated the prognostic value of quantitative histopathology in a retrospective study of 98 "low-risk" @entity0 @entity1 (T1+2N0M0) with a median follow-up of 9 years. An interactive video system and stereological and morphometric techniques were used to obtain estimates of four nuclear features (mean volume, mean profile area, volume fraction, and profile density), and two mitotic counts [ @entity4 ( @entity4 ) and @entity3 ( @entity3 )]. All measurements were performed in fields of vision sampled systematically from the whole @entity2 area of a routine histological section. Histological grade, histological type, and @entity5 receptor (ER) status was reassessed, whereas @entity2 diameter and age at diagnosis were recorded from the files. We found that all quantitative histopathological variables and ER status were correlated with histological grade. Single-factor prognostic analyses showed a highly significant value of @entity4 (2p = 0.001) and a marginally significant value of @entity3 (2p = 0.09), whereas no other variable approached statistical significance (2p > or = 0.25). In a multivariate Cox analysis, @entity4 was the only parameter of significant independent prognostic value (2p = 0.03). Thus, the prognostic value of nuclear features found in previous studies could not be reproduced, whereas the marked value of mitotic counts for prediction of the outcome in @entity1 with @entity0 was confirmed. Mitotic counts are easily obtained and may be of clinical value for identification of high-risk cases among @entity1 with @entity0 .

title: Quantitative histopathology in XXXX . Prognostic significance of mitotic counts.

answer: @entity0


abstract: BACKGROUND: Comparisons were made between two groups of anorectic @entity0 , 'non-white' and 'white', on a variety of clinical and social characteristics. METHOD: The study is based on a 34-year long database (1960-93) associated with a national tertiary referral centre. Thirty-six non-white @entity0 meeting DSM-III-R criteria for @entity2 ( @entity2 ) and five with 'partial syndrome' are compared with a white group comprising 944 @entity0 with full syndrome. RESULTS: The main finding is clinical similarity between the two groups, extending to social class and pathological patterns of family relationship. The non-whites are shorter in stature (P = 0.004) and report earlier menarche (P = 0.004); they are younger at presentation (P < 0.001), somewhat less emaciated, and practice veganism slightly more commonly; they less often acknowledge sensitivity to 'fatness' (P < 0.003). This sensitivity was exposed later whenever treatment involved substantial @entity1 . The proportion of non-white cases accepted for assessment has not changed in respect of year of onset (around 6%) for the last 20 years, or year of presentation (around 6-7%) over the last 15 years. There was a tendency for non-white @entity0 to be referred earlier in their illness. CONCLUSIONS: The clinical and background profiles of non-white and white anorectics are generally similar. The numbers arising and presenting have not changed recently. Non-white @entity0 apparently have as ready access as white @entity0 to assessment and treatment by us.

title: XXXX in 'non-white' populations.

answer: @entity2


abstract: Moderate @entity7 has been shown to improve neurologic outcomes in both fluid-percussion and @entity4 models of experimental @entity6 . Based upon initial clinical work, it was concluded that at temperatures < 32 degrees C, @entity0 with severe @entity6 were at increased risk of @entity5 , and that rapid rewarming immediately postinjury predisposed to intracranial pressure increases. Subsequent clinical studies of moderate @entity7 (32 degrees C) for 24- to 48-hr duration with slow rewarming in @entity0 @entity6 showed indications of neurologic improvement and a low incidence of @entity7 -related complications. Based upon the strengths of both laboratory and clinical data, a multicenter (nine centers), randomized, prospective trial testing moderate @entity7 in @entity0 with severe @entity6 has been organized. This trial, funded by National Institutes of Health, National Institute of @entity1 and @entity3 , began on October 20, 1994. Five hundred @entity0 are to be treated in an intent-to-treat protocol using standard management at normothermia versus standard management at @entity7 . The trial is designed to detect an absolute shift of 12% in the percentage of @entity0 achieving satisfactory outcome (good recovery/moderate disability) at a power of 85% at 6 months postinjury. The efficacy of hyperbaric @entity2 administered every 8 hrs for 1-hr duration for a 2-wk period has also been tested in @entity0 after severe @entity6 . While the mortality rate was reduced in the treated group, the percentage of favorable outcomes was unchanged. Further studies are in progress.

title: @entity7 and hyperbaric XXXX as treatment modalities for severe head injury.

answer: @entity2


abstract: Moderate @entity7 has been shown to improve neurologic outcomes in both fluid-percussion and @entity4 models of experimental @entity6 . Based upon initial clinical work, it was concluded that at temperatures < 32 degrees C, @entity0 with severe @entity6 were at increased risk of @entity5 , and that rapid rewarming immediately postinjury predisposed to intracranial pressure increases. Subsequent clinical studies of moderate @entity7 (32 degrees C) for 24- to 48-hr duration with slow rewarming in @entity0 @entity6 showed indications of neurologic improvement and a low incidence of @entity7 -related complications. Based upon the strengths of both laboratory and clinical data, a multicenter (nine centers), randomized, prospective trial testing moderate @entity7 in @entity0 with severe @entity6 has been organized. This trial, funded by National Institutes of Health, National Institute of @entity1 and @entity3 , began on October 20, 1994. Five hundred @entity0 are to be treated in an intent-to-treat protocol using standard management at normothermia versus standard management at @entity7 . The trial is designed to detect an absolute shift of 12% in the percentage of @entity0 achieving satisfactory outcome (good recovery/moderate disability) at a power of 85% at 6 months postinjury. The efficacy of hyperbaric @entity2 administered every 8 hrs for 1-hr duration for a 2-wk period has also been tested in @entity0 after severe @entity6 . While the mortality rate was reduced in the treated group, the percentage of favorable outcomes was unchanged. Further studies are in progress.

title: XXXX and hyperbaric @entity2 as treatment modalities for severe head injury.

answer: @entity7


abstract: BACKGROUND: We describe the transpelvic rectus abdominis musculocutaneous flap for closing large, often irradiated, perineal defects in @entity0 with @entity1 . METHODS: We studied 9 @entity0 and 17 @entity0 who underwent wide excision of advanced T3 and T4 @entity1 and who had preoperative chemotherapy, radiotherapy, or both. After @entity1 ablation, we used a transpelvic rectus abdominis musculocutaneous flap to fill pelvic dead space and primarily close the perineal wounds. Twelve simultaneous vaginal reconstructions were performed. RESULTS: Wounds healed promptly in 14 @entity0 . Healing was delayed in the remaining 12 @entity0 due to poor flap adherence to irradiated tissue beds (9), complete flap loss (2), or partial flap loss (1). @entity4 was associated with the combination of @entity2 and prior irradiation. Other perioperative complications included localized abdominal wound infection (2), enterocutaneous @entity5 (1), and abdominal herniation (1). @entity3 was controlled in 20 of 26 @entity0 . Mean follow-up was 22 months. CONCLUSION: Transpelvic rotation of the rectus abdominis musculocutaneous flap facilitates healing large, difficult, perineal wounds, resulting from @entity1 ablation.

title: Perineal wound closure with the rectus abdominis musculocutaneous flap after XXXX ablation.

answer: @entity1


abstract: @entity5 drugs can be used to produce a loss of cochlear hair cells to create animal models of @entity6 . However, to the best of our knowledge, there is no report on the establishment of a @entity1 @entity6 model through the combined application of @entity3 and loop diuretics. The aim of this study was to use single or combined administration of @entity4 and @entity8 to establish @entity1 models of @entity6 . The @entity1 received intravenous injections of different doses of @entity4 and/or intramuscular injections of @entity8 . The auditory brainstem response was measured to determine the hearing threshold after drug application. Immunocytochemistry and confocal microscopy were performed to evaluate inner ear morphology. In the group receiving combined administration of @entity4 and @entity8 , the auditory brainstem response threshold showed significant elevation 3 days after administration, higher than that produced by @entity4 or @entity8 alone. The hair cells showed varying degrees of injury, from the apical turn to the basal turn of the cochlea and from the outer hair cells to the inner hair cells. The @entity7 cells maintained a normal morphology during the first week after the hair cells completely disappeared, and then gradually degenerated. After 2 months, the majority of @entity7 cells disappeared, but a few remained. These findings demonstrate that the combined administration of @entity4 and @entity8 has a synergistic @entity5 effect, and that these drugs can produce hair cell loss and @entity2 in @entity1 . These findings suggest that even in @entity0 with severe @entity6 , electronic cochlear implants may partially restore hearing.

title: An efficient strategy for establishing a model of sensorineural deafness in XXXX .

answer: @entity1


abstract: @entity1 of peripheral nerve are largely neuroectodermal in nature and derived from 2 elements of nerve, Schwann or perineurial cells. In contrast, @entity2 affecting peripheral nerve are rare and are derived mainly from epineurial connective tissue. The spectrum of the latter is broad and includes @entity5 , @entity7 , and even @entity8 . Of @entity4 , the vast majority are primary @entity4 . Malignancies of mesenchymal type are much less common. To date, only 12 cases of @entity6 of nerve have been described. Whereas in the past, parallels were drawn between @entity6 and @entity1 , an uncommon form of @entity3 , molecular genetics have since clarified the distinction. Herein, we report 10 additional examples of molecularly confirmed @entity6 , all arising within minor or major nerves. Affecting 7 female and 3 male @entity0 , 4 @entity1 occurred in pediatric @entity0 . Clinically and radiologically, most lesions were initially thought to be @entity9 . On reinterpretation of imaging, they were considered indeterminate in nature with some features suspicious for @entity1 . @entity6 of nerve, albeit rare, seems to behave in a manner similar to its more common, soft tissue counterpart. Those affecting nerve have a variable prognosis. Definitive recommendations regarding surgery and adjuvant therapies await additional reports and long-term follow-up. The literature is reviewed and a meta-analysis is performed with respect to clinicopathologic features versus outcome.

title: XXXX of nerve.

answer: @entity6


abstract: BACKGROUND: When suffering a @entity2 ( @entity2 ), the @entity0 and family face numerous challenges regardless of socio-economic level. The stigmatisation of @entity0 with disabilities has been reported, however, reports from Southern Africa are largely lacking. PURPOSE: To explore the experiences of living with a traumatic @entity2 in Botswana concerning perceived attitudes, obstacles and challenges. METHOD: A qualitative approach with semi-structured interviews was conducted. Thirteen community-dwelling @entity0 who have lived with an @entity2 for at least two years participated. RESULTS: A theoretical model was formed that illustrate the associations between the core category, Self, and the categories Relationships and Society. The model illustrates that personal resources, including a strong identity and a positive attitude, are crucial to the experience of inclusion in the community. A supportive family, a source of income, and faith were strong facilitators, while inaccessibility and devaluing attitudes were barriers. Having a disability led to increased risk of poverty and social exclusion. CONCLUSION: This study emphasised the importance of personal resources, family support, and improved accessibility to facilitate inclusion in the society. Informants requested legislation to advocate for the rights of @entity0 with disabilities to be respected, with the aim of moving towards an equal accessible society. Implications for Rehabilitation Reclaiming or restructuring one's identity after a @entity2 is crucial for the @entity0 's ability to move on and develop beneficial coping strategies. Support from family and friends, staff and peer support are crucial parts in that process. Spirituality, values, needs and coping strategies vary profoundly among @entity0 sustaining disabling @entity1 . In striving to optimise care, rehabilitation staff needs to be attentive to the personal resources and preferences to be able to individualise care, encounter, and facilitate transition back to the community. Family members play a crucial part in rehabilitation. It is essential for the @entity0 ' well-being and care that they get explicit descriptions of the @entity0 's abilities. Living in a well-adapted home will facilitate well-being, independence, and return to work. Rehabilitation staff needs to focus their efforts on making this successful prior to discharge from hospital.

title: 'The moment I leave my home - there will be massive challenges': experiences of living with a XXXX in Botswana.

answer: @entity2


abstract: OBJECTIVE: To determine whether (diagnostic and interventional) ultrasound imaging can be used to provide visual feedback affecting treatment outcome ( @entity1 and disability). DESIGN: Controlled clinical trial. SUBJECTS: A total of 52 @entity0 with (ultrasonographically confirmed) symptomatic @entity7 were enrolled. METHODS: The cysts were drained under ultrasound guidance and, if necessary, @entity2 injections were given on the follow-up visit. In group I (n   =   26) the @entity0 did not observe the procedures on the ultrasound (US) screen. In group II (n   =   26) the US images/videos were shown and explained to the @entity0 . The @entity0 were included in one of the groups consecutively, unless they refused the protocol of that group. Treatment outcome was assessed via US measurements, aspirate volumes, visual analogue scale (VAS) (knee @entity1 , procedure discomfort), Western Ontario and McMaster Universities @entity4 Index (WOMAC), @entity6 ( @entity6 ), Kellgren-Lawrence grading scale, Hospital Anxiety and @entity3 Scale, and @entity5 intake. RESULTS: The 2 groups were similar regarding US measurements, aspirate volume and @entity5 use (p-values >   0.05). In both groups all VAS (p   <   0.001) and WOMAC (p   <   0.05) scores decreased after treatment. Although initial VAS and WOMAC scores were similar between the groups, all VAS/WOMAC scores, except VAS-2, WOMAC-2 @entity1 , and WOMAC-3 stiffness, were significantly lower in group II (all p   <   0.05). Initial @entity6 scores were similar between the groups; however, group II had significantly lower scores at visits 2 and 3. CONCLUSION: In @entity0 with @entity7 (diagnostic/interventional) US imaging can be used as a simple means of visual biofeedback, favourably affecting the treatment outcome ( @entity1 and disability).

title: Effects of Sono-feedback during aspiration of XXXX : A controlled clinical trial.

answer: @entity7


abstract: @entity0 who have @entity4 ( @entity4 ) are frequently hospitalized for long-term intravenous (IV) treatment. We evaluated clinical effectiveness of the Drum-Cartridge Catheter (Abbott Laboratories) for such @entity0 . The catheter is placed peripherally under local anesthesia via an antecubital vein into the superior vena cava or right atrium. @entity0 who were more than 10 years of age and who were hospitalized for IV antibiotic therapy and/or IV hyperalimentation were studied. All but 2 @entity0 had @entity4 . Using an aseptic technique the catheters were inserted into the basilic or cephalic vein. Chest radiographs were used to confirm the final location of the catheter. Catheters were used to administer IV antibiotics, hyperalimentation, and lipids. There were 38 catheterizations in 23 @entity0 ; several @entity0 had repeated insertions at later admissions. The success rate of insertion was 86% with 31 of the 38 insertions initially located either in the superior vena cava or right atrium. Mean duration of catheterization was 15.4 days (range 5-49 days). No major complications such as @entity1 , catheter or clot @entity3 , pneumothorax, vascular perforation, or @entity2 occurred in the @entity0 who had DF. Complications that required displacement of catheter into the axillary vein (1 @entity0 ), and cracked catheter hub (1 @entity0 ). This study shows that the Drum-Cartridge Catheter can be used easily for IV therapy of @entity0 who have @entity4 for a long duration, repeatedly, and with no major complications.

title: Peripherally inserted central venous catheters for treatment of XXXX .

answer: @entity4


abstract: OBJECTIVE: To assess the relative contributions of changes in vascular tone and changes in cardiac function to hemodynamic recovery from @entity5 . DESIGN: Case series, observational study. SETTING: Multidisciplinary department of intensive care in an academic hospital. @entity0 : Sixty-seven @entity0 with @entity5 (prolonged @entity7 , signs of tissue hypoperfusion, signs of @entity4 , suspected source of @entity3 , or documented @entity10 ). In addition to the antibiotic therapy and the removal of the source of @entity4 whenever possible, each @entity0 received intravenous fluids and vasoactive agents ( @entity8 , @entity9 , and @entity6 ). Each @entity0 was also treated with mechanical ventilation. Twenty-four (36%) @entity0 survived their intensive care unit course. INTERVENTIONS: Hemodynamic measurements were obtained at baseline, after initial resuscitation (as soon as apparent hemodynamic stability was achieved), after 12 hrs, and after 24 hrs. MEASUREMENTS AND MAIN RESULTS: There were no significant differences in hemodynamic or @entity1 -derived variables at baseline between the survivors and the nonsurvivors. During the initial resuscitation period, only the survivors demonstrated a significant increase in mean arterial pressure (from 69 +/- 17 to 82 +/- 18 mm Hg; p < .02) and left @entity2 work index (from 25.2 +/- 11.0 to 35.5 +/- 19.4 g.m/m2; p < .05). The increases in cardiac index and systemic vascular resistance were greater in the survivors than in the non-survivors, but the differences did not reach statistical significance. Study of the left ventricular function curves indicated an improvement of left ventricular function in the survivors but not in the nonsurvivors. CONCLUSION: An early improvement in left ventricular function is a hallmark of the survivors from @entity5 .

title: Early hemodynamic course of XXXX .

answer: @entity5


abstract: BACKGROUND: Few studies have evaluated the histopathologic features of cutaneous extranodal natural killer (NK)/ @entity5 (ENKTL), and the histopathologic spectrum of this disease according to its clinical morphology remains unclear. OBJECTIVE: This study investigated the differences in pathologic findings of cutaneous ENKTL depending on clinical morphology. METHODS: A total of 41 cases of cutaneous ENKTL were included. @entity3 were classified according to clinical morphology as: (i) nodular lesions, (ii) @entity6 or @entity4 -like swellings and (iii) erythematous to @entity8 patches. Histopathologic variables were compared between groups. RESULTS: Perivascular infiltration of @entity1 cells and vasculopathy in the dermis and subcutaneous layer were common microscopic findings irrespective of clinical morphology. @entity8 patches were mainly composed of small-sized @entity1 cells, whereas medium- to large- @entity1 cells were predominant in lesions of other clinical morphologies. The density of @entity1 cell infiltration was significantly higher in @entity6 or @entity2 or nodular lesions compared with erythematous to @entity8 patches. A @entity7 -like pattern and angiocentricity were less common in patch lesions than in @entity6 -like @entity0 . CONCLUSION: There is a histopathologic spectrum of cutaneous ENKTL that is dependent on the clinical morphology.

title: Comparative histopathologic analysis of cutaneous extranodal natural killer/ XXXX according to their clinical morphology.

answer: @entity5


abstract: Because @entity2 ( @entity2 ) and its receptor play a pivotal role in many @entity1 , it is an attractive target for the design of inhibitors. Here we present a new family of bioisostere inhibitors, based on the structure of @entity8 . @entity8 is a substrate-competitive inhibitor of the @entity5 ( @entity5 ), with an IC50 = 61 nM in a cell-free kinase assay (Blum, G., Gazit, A., and Levitzki, A. (2000) Biochemistry 39, 15705-15712). @entity8 is a low molecular weight compound containing two @entity6 rings, which are sensitive to oxidation in cells. We have therefore prepared and examined @entity6 bioisosteres of @entity8 . These @entity8 bioisosteres possess similar biological properties to @entity8 ; they inhibit @entity5 by a substrate-competitive mechanism and are non-competitive vis    vis @entity4 . They inhibit @entity5 kinase activity in the sub-micromolar concentration range in cell-free assays. @entity2 induced @entity5 autophosphorylation; @entity7 phosphorylation and protein kinase B activation are inhibited at a low micromolar concentration range when applied to intact cells. These inhibitors also block the formation of colonies in soft agar by prostate and @entity0 cells. The ability to replace @entity6 groups with a moiety that is more stable in cells may aid in developing non- @entity6 -containing substrate-competitive inhibitors targeted toward @entity5 and possibly against other protein- @entity3 kinases.

title: Development of new XXXX kinase inhibitors using @entity6 mimics.

answer: @entity5


abstract: Because @entity2 ( @entity2 ) and its receptor play a pivotal role in many @entity1 , it is an attractive target for the design of inhibitors. Here we present a new family of bioisostere inhibitors, based on the structure of @entity8 . @entity8 is a substrate-competitive inhibitor of the @entity5 ( @entity5 ), with an IC50 = 61 nM in a cell-free kinase assay (Blum, G., Gazit, A., and Levitzki, A. (2000) Biochemistry 39, 15705-15712). @entity8 is a low molecular weight compound containing two @entity6 rings, which are sensitive to oxidation in cells. We have therefore prepared and examined @entity6 bioisosteres of @entity8 . These @entity8 bioisosteres possess similar biological properties to @entity8 ; they inhibit @entity5 by a substrate-competitive mechanism and are non-competitive vis    vis @entity4 . They inhibit @entity5 kinase activity in the sub-micromolar concentration range in cell-free assays. @entity2 induced @entity5 autophosphorylation; @entity7 phosphorylation and protein kinase B activation are inhibited at a low micromolar concentration range when applied to intact cells. These inhibitors also block the formation of colonies in soft agar by prostate and @entity0 cells. The ability to replace @entity6 groups with a moiety that is more stable in cells may aid in developing non- @entity6 -containing substrate-competitive inhibitors targeted toward @entity5 and possibly against other protein- @entity3 kinases.

title: Development of new @entity5 kinase inhibitors using XXXX mimics.

answer: @entity6


abstract: Male and female @entity1 received @entity7 daily by @entity6 oil gavage for 10 or 90 consecutive days. The 10-day study doses were 0, 37, 147, 368 and 735 mg/kg; the 90-day study doses were 0, 9, 37, 147 and 588 mg/kg. In the 10-day study, there was a significant @entity3 of body weight in both sexes at 735 mg/kg. Liver weights were significantly increased in both sexes at 368 and 735 mg/kg. Serum @entity2 levels were significantly elevated in both sexes at 368 and 735 mg/kg. Histopathological evaluation revealed centrolobular hepatocellular degeneration at 368 mg/kg in males and 735 mg/kg in females. In the 90-day study, body weights were significantly depressed in both sexes at 588 mg/kg. Normalization of food and water consumption by final body weight indicated that at 588 mg/kg both sexes had increased food and water consumption relative to controls. Absolute and relative liver weights were significantly increased in both sexes at 147 and 588 mg/kg. Relative kidney weights were significantly higher in both sexes at 588 mg/kg and in males at 147 mg/kg. Serum @entity2 and @entity4 levels were significantly elevated over controls in females at 37, 147, and 588 mg/kg, and in males at all dose levels. Histopathological evaluation at 147 and/or 588 mg/kg demonstrated liver and @entity5 in both sexes, and @entity0 in males. A NOAEL was not firmly established.

title: Toxicity studies of XXXX in @entity1 .

answer: @entity7


abstract: Male and female @entity1 received @entity7 daily by @entity6 oil gavage for 10 or 90 consecutive days. The 10-day study doses were 0, 37, 147, 368 and 735 mg/kg; the 90-day study doses were 0, 9, 37, 147 and 588 mg/kg. In the 10-day study, there was a significant @entity3 of body weight in both sexes at 735 mg/kg. Liver weights were significantly increased in both sexes at 368 and 735 mg/kg. Serum @entity2 levels were significantly elevated in both sexes at 368 and 735 mg/kg. Histopathological evaluation revealed centrolobular hepatocellular degeneration at 368 mg/kg in males and 735 mg/kg in females. In the 90-day study, body weights were significantly depressed in both sexes at 588 mg/kg. Normalization of food and water consumption by final body weight indicated that at 588 mg/kg both sexes had increased food and water consumption relative to controls. Absolute and relative liver weights were significantly increased in both sexes at 147 and 588 mg/kg. Relative kidney weights were significantly higher in both sexes at 588 mg/kg and in males at 147 mg/kg. Serum @entity2 and @entity4 levels were significantly elevated over controls in females at 37, 147, and 588 mg/kg, and in males at all dose levels. Histopathological evaluation at 147 and/or 588 mg/kg demonstrated liver and @entity5 in both sexes, and @entity0 in males. A NOAEL was not firmly established.

title: Toxicity studies of @entity7 in XXXX .

answer: @entity1


abstract: Although the mechanisms underlying the use-dependent inhibition of @entity0 receptors (AMPARs) by barbiturates are not well understood, it has generally been assumed to involve open channel block. We examined the properties of the inhibition of AMPARs by the barbiturate @entity3 (PB) in acutely isolated and cultured hippocampal neurons. PB caused a use- and concentration-dependent inhibition (IC50 = 20.7 microM) of AMPAR-mediated currents evoked by @entity2 . Contrary to the properties of an open channel blocker, the inhibition by PB developed with double exponential kinetics was reduced under conditions that favor the open channel state of AMPARs and was independent of membrane voltage. In addition, the inhibition was reduced at basic pH, indicating that the uncharged form of PB is active at AMPARs. Preventing AMPAR desensitization with @entity4 reduced the potency of inhibition by PB and prevented its trapping after the removal of agonist. PB preferentially reduced the steady-state (IC50 = 92.8 microM), rather than peak (IC50 > 1 mM) component of responses evoked by @entity1 and accelerated the onset of desensitization in a concentration-dependent manner. Miniature excitatory postsynaptic currents recorded from cultured hippocampal neurons, the time course of which is minimally influenced by desensitization, are not inhibited by PB. The sensitivity of AMPAR-mediated synaptic responses to inhibition by PB therefore depends on the contribution of desensitization to these events. Our results suggest that PB does not act as an open channel blocker of AMPARs. Rather, the sensitivity, use dependence, and trapping of inhibition by PB are determined by AMPARs desensitization.

title: Desensitization of @entity0 ( @entity0 ) receptors facilitates use-dependent inhibition by XXXX .

answer: @entity3


abstract: Although the mechanisms underlying the use-dependent inhibition of @entity0 receptors (AMPARs) by barbiturates are not well understood, it has generally been assumed to involve open channel block. We examined the properties of the inhibition of AMPARs by the barbiturate @entity3 (PB) in acutely isolated and cultured hippocampal neurons. PB caused a use- and concentration-dependent inhibition (IC50 = 20.7 microM) of AMPAR-mediated currents evoked by @entity2 . Contrary to the properties of an open channel blocker, the inhibition by PB developed with double exponential kinetics was reduced under conditions that favor the open channel state of AMPARs and was independent of membrane voltage. In addition, the inhibition was reduced at basic pH, indicating that the uncharged form of PB is active at AMPARs. Preventing AMPAR desensitization with @entity4 reduced the potency of inhibition by PB and prevented its trapping after the removal of agonist. PB preferentially reduced the steady-state (IC50 = 92.8 microM), rather than peak (IC50 > 1 mM) component of responses evoked by @entity1 and accelerated the onset of desensitization in a concentration-dependent manner. Miniature excitatory postsynaptic currents recorded from cultured hippocampal neurons, the time course of which is minimally influenced by desensitization, are not inhibited by PB. The sensitivity of AMPAR-mediated synaptic responses to inhibition by PB therefore depends on the contribution of desensitization to these events. Our results suggest that PB does not act as an open channel blocker of AMPARs. Rather, the sensitivity, use dependence, and trapping of inhibition by PB are determined by AMPARs desensitization.

title: Desensitization of XXXX ( @entity0 ) receptors facilitates use-dependent inhibition by @entity3 .

answer: @entity0


abstract: Although the mechanisms underlying the use-dependent inhibition of @entity0 receptors (AMPARs) by barbiturates are not well understood, it has generally been assumed to involve open channel block. We examined the properties of the inhibition of AMPARs by the barbiturate @entity3 (PB) in acutely isolated and cultured hippocampal neurons. PB caused a use- and concentration-dependent inhibition (IC50 = 20.7 microM) of AMPAR-mediated currents evoked by @entity2 . Contrary to the properties of an open channel blocker, the inhibition by PB developed with double exponential kinetics was reduced under conditions that favor the open channel state of AMPARs and was independent of membrane voltage. In addition, the inhibition was reduced at basic pH, indicating that the uncharged form of PB is active at AMPARs. Preventing AMPAR desensitization with @entity4 reduced the potency of inhibition by PB and prevented its trapping after the removal of agonist. PB preferentially reduced the steady-state (IC50 = 92.8 microM), rather than peak (IC50 > 1 mM) component of responses evoked by @entity1 and accelerated the onset of desensitization in a concentration-dependent manner. Miniature excitatory postsynaptic currents recorded from cultured hippocampal neurons, the time course of which is minimally influenced by desensitization, are not inhibited by PB. The sensitivity of AMPAR-mediated synaptic responses to inhibition by PB therefore depends on the contribution of desensitization to these events. Our results suggest that PB does not act as an open channel blocker of AMPARs. Rather, the sensitivity, use dependence, and trapping of inhibition by PB are determined by AMPARs desensitization.

title: Desensitization of @entity0 ( XXXX ) receptors facilitates use-dependent inhibition by @entity3 .

answer: @entity0


abstract: The contraction of smooth muscle is regulated primarily by intracellular @entity0 signal. It is well established that the elevation of the cytosolic @entity0 level activates @entity3 , which phosphorylates 20 kDa regulatory @entity1 light chain and activates @entity1 ATPase. The simultaneous measurement of cytosolic @entity0 concentration and force development revealed that the alteration of the @entity0 -sensitivity of the contractile apparatus as well as the @entity0 signal plays a critical role in the regulation of smooth muscle contraction. The fluctuation of an extent of @entity1 phosphorylation for a given change in @entity0 concentration is considered to contribute to the major mechanisms regulating the @entity0 -sensitivity. The level of @entity1 phosphorylation is determined by the balance between phosphorylation and dephosphorylation. The phosphorylation level for a given @entity0 elevation is increased either by @entity0 -independent activation of phosphorylation process or inhibition of dephosphorylation. In the last decade, the isolation and cloning of @entity1 phosphatase facilitated the understanding of regulatory mechanism of dephosphorylation process at the molecular level. The inhibition of @entity1 phosphatase can be achieved by (1) alteration of hetrotrimeric structure, (2) phosphorylation of 110 kDa regulatory subunit @entity5 at the specific site and (3) inhibitory protein @entity4 upon its phosphorylation. Rho-kinase was first identified to phosphorylate @entity5 , and later many kinases were found to phosphorylate @entity5 and inhibit dephosphorylation of @entity1 . Similarly, the phosphorylation of @entity4 can be catalysed by multiple kinases. Moreover, the @entity1 light chain can be phosphorylated by not only authentic @entity1 light chain kinase in a @entity0 -dependent manner but also by multiple kinases in a @entity0 -independent manner, thus adding a novel mechanism to the regulation of the @entity0 -sensitivity by regulating the phosphorylation process. It is now clarified that the @entity2 network is involved in the regulation of @entity1 phosphorylation and dephosphorylation. However, the physiological role of each component remains to be determined. One approach to accomplish this purpose is to investigate the effects of the dominant negative mutants of the signalling molecule on the smooth muscle contraction. In this regards, a protein transduction technique utilizing the cell-penetrating peptides would provide a useful tool. In the preliminary study, we succeeded in introducing a fragment of @entity5 into the arterial strips, and found enhancement of contraction.

title: @entity2 network in the regulation of phosphorylation and dephosphorylation of smooth muscle XXXX light chain.

answer: @entity1


abstract: The contraction of smooth muscle is regulated primarily by intracellular @entity0 signal. It is well established that the elevation of the cytosolic @entity0 level activates @entity3 , which phosphorylates 20 kDa regulatory @entity1 light chain and activates @entity1 ATPase. The simultaneous measurement of cytosolic @entity0 concentration and force development revealed that the alteration of the @entity0 -sensitivity of the contractile apparatus as well as the @entity0 signal plays a critical role in the regulation of smooth muscle contraction. The fluctuation of an extent of @entity1 phosphorylation for a given change in @entity0 concentration is considered to contribute to the major mechanisms regulating the @entity0 -sensitivity. The level of @entity1 phosphorylation is determined by the balance between phosphorylation and dephosphorylation. The phosphorylation level for a given @entity0 elevation is increased either by @entity0 -independent activation of phosphorylation process or inhibition of dephosphorylation. In the last decade, the isolation and cloning of @entity1 phosphatase facilitated the understanding of regulatory mechanism of dephosphorylation process at the molecular level. The inhibition of @entity1 phosphatase can be achieved by (1) alteration of hetrotrimeric structure, (2) phosphorylation of 110 kDa regulatory subunit @entity5 at the specific site and (3) inhibitory protein @entity4 upon its phosphorylation. Rho-kinase was first identified to phosphorylate @entity5 , and later many kinases were found to phosphorylate @entity5 and inhibit dephosphorylation of @entity1 . Similarly, the phosphorylation of @entity4 can be catalysed by multiple kinases. Moreover, the @entity1 light chain can be phosphorylated by not only authentic @entity1 light chain kinase in a @entity0 -dependent manner but also by multiple kinases in a @entity0 -independent manner, thus adding a novel mechanism to the regulation of the @entity0 -sensitivity by regulating the phosphorylation process. It is now clarified that the @entity2 network is involved in the regulation of @entity1 phosphorylation and dephosphorylation. However, the physiological role of each component remains to be determined. One approach to accomplish this purpose is to investigate the effects of the dominant negative mutants of the signalling molecule on the smooth muscle contraction. In this regards, a protein transduction technique utilizing the cell-penetrating peptides would provide a useful tool. In the preliminary study, we succeeded in introducing a fragment of @entity5 into the arterial strips, and found enhancement of contraction.

title: XXXX network in the regulation of phosphorylation and dephosphorylation of smooth muscle @entity1 light chain.

answer: @entity2


abstract: Language comprehension, measured by the Luria-Nebraska Relational Concepts Factor Scale, was evaluated twice in 15 male DSM-III-R @entity1 @entity0 during a controlled double-blind @entity5 maintenance (without anticholinergics) and placebo replacement protocol. Fifteen male normal controls were tested once. @entity0 and controls were matched on age and education. Language comprehension was significantly reduced in @entity0 under both pharmacologic conditions, as compared with controls. @entity0 ' comprehension accuracy did not differ significantly between neuroleptic-treatment and placebo replacement conditions. @entity0 ' comprehension accuracy was independent of positive symptoms, @entity2 , measures of clinical course, and CSF and plasma @entity4 . Comprehension accuracy was also not associated with @entity0 ' educational level or WAIS-R measures of their intellectual and short-term memory functioning. @entity0 ' comprehension performance was significantly associated only with the negative symptom anhedonia-asociality during @entity5 maintenance. Thus, language comprehension in @entity1 @entity0 was independent of changes in pharmacologic treatment and the positive symptoms of @entity3 . Results suggest language comprehension may represent a stable or trait characteristic in @entity1 .

title: Language comprehension in XXXX : trait or state indicator?

answer: @entity1


abstract: @entity7 is a rare @entity1 composed of cells with epithelial characteristics in various differentiation patterns surrounded by fibrous cells. Evidence as to whether this @entity1 should be designated as an epithelial bone @entity1 or a @entity3 with both epithelial and mesenchymal features is lacking. In this study the nature of the mesenchymal and epithelial components of @entity5 was investigated by DNA flow cytometry, DNA image cytometry, @entity4 immunohistochemistry, and polymerase chain reaction-based loss of heterozygosity detection at the @entity4 locus. Specimens from 6 of 15 @entity0 (40%) analyzed by flow cytometry had an aneuploid DNA index. Image cytometry analysis of Feulgen-stained paraffin sections of 6 aneuploid and 2 diploid @entity1 revealed that aneuploid nuclei were detected in cells with an epithelial phenotype only, whereas all fibrous cells were diploid. Immunohistochemistry for @entity4 on specimens from 25 @entity0 revealed moderate or strong immunoreactivity in 12 @entity1 (48%) restricted to the epithelial cells. Loss of heterozygosity at the @entity4 locus could be confirmed in the epithelial component of an immunohistochemically @entity4 -positive @entity1 . Additionally, sections of 7 lung metastases were studied histologically. Only keratin-positive epithelial cells, predominantly in the spindle cell pattern, were present in these metastases, whereas the osteofibrous tissue present in the @entity1 was not detected. These results suggest that either @entity5 consists of a malignant epithelial part with a reactive @entity6 or that the malignant epithelial cells develop next to a proliferating benign fibrous component. Additional analysis of common @entity2 in the fibrous and epithelial cells of @entity5 is therefore indicated.

title: DNA aberrations in the epithelial cell component of XXXX .

answer: @entity7


abstract: INTRODUCTION: Catheter ablation has become a well-established therapy for isthmus-dependent right @entity1 ( @entity1 ). Recently, mapping and ablation of @entity1 have been performed using sophisticated three-dimensional mapping systems, such as electroanatomic and noncontact mapping systems. The LocaLisa system enables nonfluoroscopic navigation of intracardiac electrode catheters based on impedance changes related to catheter movements in transthoracic current fields. The aim of this randomized prospective study was to compare the efficacy of the LocaLisa system with the conventional mapping/ablation approach for radiofrequency ablation of @entity1 . METHODS AND RESULTS: Fifty consecutive @entity0 with @entity1 (39 @entity0 and 11 @entity0 ; age 65 +/- 10 years) were studied. The @entity0 were randomly assigned to undergo radiofrequency ablation guided by a conventional fluoroscopy-based approach (24 @entity0 ) or by the LocaLisa system (26 @entity0 ). Ablation success rate and documentation of bidirectional isthmus block were 100% in both groups. Compared with fluoroscopy-guided approaches, LocaLisa-guided procedures demonstrated a reduction in total fluoroscopy time from 15.9 +/- 10.6 minutes to 7.5 +/- 6.5 minutes (P < 0.005). Total fluoroscopy dosage was reduced from 21.0 +/- 19.8 to 8.7 +/- 9.5 Gycm2 (P < 0.05). Fluoroscopy time required for ablation was significantly shortened in the LocaLisa group (2.6 +/- 2.6 min) compared with the conventional approach group (11 +/- 10 min, P < 0.0005). In 9 (35%) of 26 @entity0 , the ablation could be performed with a fluoroscopy time < or = 1 minute. There were no significant differences with regard to the number of radiofrequency applications, fluoroscopy time needed for diagnostic reasons, total procedure time, or other ablation data. CONCLUSION: Compared with the conventional approach, the LocaLisa system significantly reduces the fluoroscopy times needed for ablation of typical @entity1 .

title: LocaLisa catheter navigation reduces fluoroscopy time and dosage in ablation of XXXX : a prospective randomized study.

answer: @entity1


abstract: PURPOSE: Comparative analysis of cardiac weight (CW) in @entity0 with @entity1 , with or without @entity6 by @entity5 in the @entity7 ( @entity7 ). METHODS: The CW has been studied in 96 necropsied individuals with @entity1 . Among them, 48 of them had @entity5 nests on the wall of the @entity7 and the other 48 @entity0 did not have nests in the @entity7 . Later, this sample was paired for sex, age and anatomo-clinical form, resulting in 60 @entity0 . Among these @entity0 , 30 of them had @entity5 nests on the walls of the @entity7 and the other 30 did not have. RESULTS: The CW of @entity4 @entity0 which had nests of @entity5 in the @entity7 , was 484.8 +/- 146.0g, while in the ones that did not have the nests on the walls of the @entity7 , the CW weight was 415.8 +/- 125.3g. This difference was statistically significant. In the first group it had a prevail of @entity3 . Subsequently to the @entity8 for sex, age and anatomo-clinical form, the CW was respectively 464.3 +/- 146.2g and 436.0 +/- 108.9g. This difference was not statistically significant. CONCLUSION: These data suggest that the @entity6 in the @entity7 , combined with other possible events intrinsic to the @entity1 @entity0 ' hearts, carries a supporting role in the increasing of the cardiac weight and in the congestive @entity2 .

title: [Cardiac weight in @entity0 with @entity1 with XXXX nests in the central vein of the adrenal glands].

answer: @entity5


abstract: PURPOSE: Comparative analysis of cardiac weight (CW) in @entity0 with @entity1 , with or without @entity6 by @entity5 in the @entity7 ( @entity7 ). METHODS: The CW has been studied in 96 necropsied individuals with @entity1 . Among them, 48 of them had @entity5 nests on the wall of the @entity7 and the other 48 @entity0 did not have nests in the @entity7 . Later, this sample was paired for sex, age and anatomo-clinical form, resulting in 60 @entity0 . Among these @entity0 , 30 of them had @entity5 nests on the walls of the @entity7 and the other 30 did not have. RESULTS: The CW of @entity4 @entity0 which had nests of @entity5 in the @entity7 , was 484.8 +/- 146.0g, while in the ones that did not have the nests on the walls of the @entity7 , the CW weight was 415.8 +/- 125.3g. This difference was statistically significant. In the first group it had a prevail of @entity3 . Subsequently to the @entity8 for sex, age and anatomo-clinical form, the CW was respectively 464.3 +/- 146.2g and 436.0 +/- 108.9g. This difference was not statistically significant. CONCLUSION: These data suggest that the @entity6 in the @entity7 , combined with other possible events intrinsic to the @entity1 @entity0 ' hearts, carries a supporting role in the increasing of the cardiac weight and in the congestive @entity2 .

title: [Cardiac weight in @entity0 with XXXX with @entity5 nests in the central vein of the adrenal glands].

answer: @entity1


abstract: PURPOSE: Comparative analysis of cardiac weight (CW) in @entity0 with @entity1 , with or without @entity6 by @entity5 in the @entity7 ( @entity7 ). METHODS: The CW has been studied in 96 necropsied individuals with @entity1 . Among them, 48 of them had @entity5 nests on the wall of the @entity7 and the other 48 @entity0 did not have nests in the @entity7 . Later, this sample was paired for sex, age and anatomo-clinical form, resulting in 60 @entity0 . Among these @entity0 , 30 of them had @entity5 nests on the walls of the @entity7 and the other 30 did not have. RESULTS: The CW of @entity4 @entity0 which had nests of @entity5 in the @entity7 , was 484.8 +/- 146.0g, while in the ones that did not have the nests on the walls of the @entity7 , the CW weight was 415.8 +/- 125.3g. This difference was statistically significant. In the first group it had a prevail of @entity3 . Subsequently to the @entity8 for sex, age and anatomo-clinical form, the CW was respectively 464.3 +/- 146.2g and 436.0 +/- 108.9g. This difference was not statistically significant. CONCLUSION: These data suggest that the @entity6 in the @entity7 , combined with other possible events intrinsic to the @entity1 @entity0 ' hearts, carries a supporting role in the increasing of the cardiac weight and in the congestive @entity2 .

title: [Cardiac weight in XXXX with @entity1 with @entity5 nests in the central vein of the adrenal glands].

answer: @entity0


abstract: OBJECTIVE: In clinical routine, some @entity0 show a bilateral hyperactive response of the @entity2 ( @entity2 ). The aim of this prospective study was to determine whether these @entity0 also show @entity3 of the linear VOR (LVOR). MATERIAL AND METHODS: In 10 @entity0 with a hyperactive @entity2 (total amplitude of post-rotatory nystagmus > 400 degrees per 30 s) and 10 healthy subjects the @entity2 (stopped after 180 s of rotation at 90 degrees/s) and vertical LVOR (amplitude 5 cm, frequency 1.2 Hz) were tested with eyes open in the dark. During vertical linear acceleration, each subject was instructed to look at an earth-fixed target and they performed vertical smooth pursuit as stationary observers. RESULTS: The mean eye velocity of the @entity2 was significantly higher in the @entity0 than the healthy subjects (19 vs 5 degrees/s; p = 0.00016). During vertical linear acceleration in darkness (49 vs 23 degrees/s; p = 0.004) and combined maculo-visual stimulation (88 vs 52 degrees/s; p = 0.007) the @entity0 showed a significantly higher mean vertical eye velocity. When vertical smooth pursuit was performed, no significant differences were registered. All 20 subjects showed a significant (p = 0.01) positive Spearmnan correlation (rs = 0.79) between the eye velocities of @entity2 and LVOR. CONCLUSION: @entity0 with a hyperactive @entity2 also showed @entity3 of the LVOR. Because two different sensory end organs and neuronal pathways are involved in these responses, a central rather than a peripheral @entity1 must be held responsible.

title: The vertical linear vestibulo-ocular reflex in XXXX with a hyperactive response during horizontal angular acceleration.

answer: @entity0


abstract: INTRODUCTION: @entity6 , reflux and @entity2 are serious complications that occur in @entity0 with @entity4 associated with @entity7 . When the bladder compliance is lost, it is imperative to carry out surgery aimed at reducing bladder storage pressure. An ileocystoplasty, and for @entity0 not suitable for intermittent catheterization, using the Mitrofanoff principle to form a continent stoma and the subsequent closure of the bladder neck, can be used. We report here, for the first time to the best of our knowledge, an association between two previously described techniques (the Mitrofanoff principle and the technique of Monti), that can solve the problem of a short appendix in @entity1 @entity0 . CASE PRESENTATION: A 33-year-old male Caucasian @entity0 with @entity7 and @entity4 developed @entity4 (4.0 mL/cm @entity5 ) while still maintaining normal renal function. A @entity4 (ileocystoplasty) with continent derivation principle (Mitrofanoff) was performed. During surgery, we found that the @entity0 's appendix was too short and was insufficient to reach the skin. We decided to make an association between the Mitrofanoff conduit and the ileal technique of Monti, through which we performed an @entity3 of the distal stump of the appendix to the bladder (with an antireflux valve). Later, the proximal stump of the appendix was anastomosed to an ileal segment of 2.0 cm that was open longitudinally and reconfigured transversally (Monti technique), modeled by a 12-Fr urethral catheter, and finally, the distal stump was sutured at the @entity0 's navel.After the procedure, a suprapubic cystostomy (22 Fr) and a Foley catheter (10 Fr) through the continent conduit were left in place. The @entity0 had recovered well and was discharged on the tenth day after surgery. He remained with the Foley catheter (through the conduit) for 21 days and cystostomy for 30 days. Six months after surgery he was continent with good bladder compliance without reflux and fully adapted to catheterization through the navel. CONCLUSION: The unpublished association between the Mitrofanoff and Monti techniques is feasible and a very useful alternative in urologic cases of derivation continent in which the @entity8 is too short to reach the skin (i.e., in @entity1 @entity0 ).

title: Using Mitrofanoff's principle and Monti's technique as a surgical option for XXXX with a continent stoma: a case report.

answer: @entity4


abstract: We used naming and pointing tests and a proverb completion task to compare two cases of @entity2 that exhibited a selective disturbance of word processing. One @entity0 had @entity3 with word comprehension difficulty due to partial ablation of the left temporal lobe and the other @entity0 had @entity2 due to @entity1 with left temporal predominance. We presented 90 pictures of common objects divided into 9 categories in the naming and pointing tests, and used 10 well-known Japanese proverbs as stimuli in the proverb completion task. Performance of the naming and pointing tests was severely impaired in both @entity0 . In the @entity0 with @entity3 , words the @entity0 could not name or point to varied from session to session and phonemic cue effects were frequently observed. The proverb completion phenomenon was positive. These findings indicate that the @entity0 had an obstruction of the access route to the intact word store or a partial rarefaction of the word store itself. In the @entity0 with @entity2 , the words the @entity0 could not name or point to were consistent from one occasion to another, and no phonemic cue effects or signs of familiarity were observed at all. The proverb completion phenomenon was totally negative. These findings indicate that the @entity0 has lost the word store itself. MR images in the case of @entity3 revealed a lesion extending from the anterior to the central portion of the inferior part of the left temporal lobe. In the case of @entity2 , the MR images displayed knife-edged focal @entity1 in the anterior aspect of both temporal lobes, more prominently on the left.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Comparison between @entity3 with word comprehension difficulty and XXXX due to @entity1 ].

answer: @entity2


abstract: We used naming and pointing tests and a proverb completion task to compare two cases of @entity2 that exhibited a selective disturbance of word processing. One @entity0 had @entity3 with word comprehension difficulty due to partial ablation of the left temporal lobe and the other @entity0 had @entity2 due to @entity1 with left temporal predominance. We presented 90 pictures of common objects divided into 9 categories in the naming and pointing tests, and used 10 well-known Japanese proverbs as stimuli in the proverb completion task. Performance of the naming and pointing tests was severely impaired in both @entity0 . In the @entity0 with @entity3 , words the @entity0 could not name or point to varied from session to session and phonemic cue effects were frequently observed. The proverb completion phenomenon was positive. These findings indicate that the @entity0 had an obstruction of the access route to the intact word store or a partial rarefaction of the word store itself. In the @entity0 with @entity2 , the words the @entity0 could not name or point to were consistent from one occasion to another, and no phonemic cue effects or signs of familiarity were observed at all. The proverb completion phenomenon was totally negative. These findings indicate that the @entity0 has lost the word store itself. MR images in the case of @entity3 revealed a lesion extending from the anterior to the central portion of the inferior part of the left temporal lobe. In the case of @entity2 , the MR images displayed knife-edged focal @entity1 in the anterior aspect of both temporal lobes, more prominently on the left.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Comparison between @entity3 with word comprehension difficulty and @entity2 due to XXXX ].

answer: @entity1


abstract: We used naming and pointing tests and a proverb completion task to compare two cases of @entity2 that exhibited a selective disturbance of word processing. One @entity0 had @entity3 with word comprehension difficulty due to partial ablation of the left temporal lobe and the other @entity0 had @entity2 due to @entity1 with left temporal predominance. We presented 90 pictures of common objects divided into 9 categories in the naming and pointing tests, and used 10 well-known Japanese proverbs as stimuli in the proverb completion task. Performance of the naming and pointing tests was severely impaired in both @entity0 . In the @entity0 with @entity3 , words the @entity0 could not name or point to varied from session to session and phonemic cue effects were frequently observed. The proverb completion phenomenon was positive. These findings indicate that the @entity0 had an obstruction of the access route to the intact word store or a partial rarefaction of the word store itself. In the @entity0 with @entity2 , the words the @entity0 could not name or point to were consistent from one occasion to another, and no phonemic cue effects or signs of familiarity were observed at all. The proverb completion phenomenon was totally negative. These findings indicate that the @entity0 has lost the word store itself. MR images in the case of @entity3 revealed a lesion extending from the anterior to the central portion of the inferior part of the left temporal lobe. In the case of @entity2 , the MR images displayed knife-edged focal @entity1 in the anterior aspect of both temporal lobes, more prominently on the left.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Comparison between XXXX with word comprehension difficulty and @entity2 due to @entity1 ].

answer: @entity3


abstract: We assessed the anatomical findings and auditory comprehension of six @entity0 with @entity4 due to medical lesions of the @entity1 . All @entity0 were right-handed and were initially mute for several hours after the onset, and they exhibited mild paresis of the right lower extremity. Their spontaneous speech was sparse and not fluent, and sometimes accompanied by @entity5 , but their articulation was normal and repetition was excellent. They had difficulty in recalling words. A diagnosis of @entity4 was made on the basis of their clinical symptoms. All @entity0 were found to have an @entity2 in the left medial frontal region by MRI and/or CT. We administered the Western Aphasia Battery and 50 line drawing pointing task in order to evaluate auditory comprehension. Based on the results we concluded that there is no @entity3 of single words when lesions are limited to the superior frontal gyrus, but that lesions extending to the middle frontal gyrus interfere with auditory comprehension of single words. Our observations indicate that the middle frontal gyrus plays an important role in auditory comprehension of single words. All of the @entity0 displayed @entity3 of sentences even when their lesions were strictly limited to the medial frontal lobe. This suggests that the medial frontal lobe plays some role in the auditory comprehension of sentences.

title: [Auditory comprehension in XXXX due to a medial lesions of the @entity1 ].

answer: @entity4


abstract: We assessed the anatomical findings and auditory comprehension of six @entity0 with @entity4 due to medical lesions of the @entity1 . All @entity0 were right-handed and were initially mute for several hours after the onset, and they exhibited mild paresis of the right lower extremity. Their spontaneous speech was sparse and not fluent, and sometimes accompanied by @entity5 , but their articulation was normal and repetition was excellent. They had difficulty in recalling words. A diagnosis of @entity4 was made on the basis of their clinical symptoms. All @entity0 were found to have an @entity2 in the left medial frontal region by MRI and/or CT. We administered the Western Aphasia Battery and 50 line drawing pointing task in order to evaluate auditory comprehension. Based on the results we concluded that there is no @entity3 of single words when lesions are limited to the superior frontal gyrus, but that lesions extending to the middle frontal gyrus interfere with auditory comprehension of single words. Our observations indicate that the middle frontal gyrus plays an important role in auditory comprehension of single words. All of the @entity0 displayed @entity3 of sentences even when their lesions were strictly limited to the medial frontal lobe. This suggests that the medial frontal lobe plays some role in the auditory comprehension of sentences.

title: [Auditory comprehension in @entity4 due to a medial lesions of the XXXX ].

answer: @entity1


abstract: Chemical sympathectomy with @entity6 (Gnt) selectively destroys the postganglionic noradrenergic neurons, whereas dopaminergic fibers and nonneural @entity5 -secreting cells are spared. As a result, the relative proportions of @entity2 (NE), @entity3 (E), and @entity1 (DA) in tissues can be differentially affected. This study was done to show the possible differences in the relative amount of @entity4 in some organs and tissues that might indicate the nature of the secretory cells from which they originate. The contents of NE, E, and DA were assessed in @entity0 neonatally treated with Gnt. Gnt-treated @entity0 showed significantly lower levels of NE (P < 0.01) in all tissues except the adrenal gland and paraganglia. @entity3 was present in all tissues with mean levels below 25 ng/g, with the exception of the adrenal gland (700 microg/gland) and paraganglia (100 ng/g). Only the heart showed lower values in Gnt-treated @entity0 . Mean DA levels were also very high in paraganglia (530 ng/g). In the Gnt-treated @entity0 , DA levels fell practically to zero except in the duodenum, mesentery, and adrenal, whereas there were high levels in the paraganglia, which were significantly different from controls. The results suggest that the three @entity4 are contained mainly in noradrenergic sympathetic fibers of muscle, white adipose tissue, heart, liver, pancreas, and spleen. The duodenum and mesentery may have dopaminergic fibers or E- and DA-containing nonneural cells. Hepatic-vagus paraganglia contain all the @entity4 in relatively high amounts in nonneural cells, and Gnt treatment raises DA levels without affecting the other @entity7 .

title: @entity3 and @entity1 colocalization with XXXX in various peripheral tissues: @entity6 effects.

answer: @entity2


abstract: Chemical sympathectomy with @entity6 (Gnt) selectively destroys the postganglionic noradrenergic neurons, whereas dopaminergic fibers and nonneural @entity5 -secreting cells are spared. As a result, the relative proportions of @entity2 (NE), @entity3 (E), and @entity1 (DA) in tissues can be differentially affected. This study was done to show the possible differences in the relative amount of @entity4 in some organs and tissues that might indicate the nature of the secretory cells from which they originate. The contents of NE, E, and DA were assessed in @entity0 neonatally treated with Gnt. Gnt-treated @entity0 showed significantly lower levels of NE (P < 0.01) in all tissues except the adrenal gland and paraganglia. @entity3 was present in all tissues with mean levels below 25 ng/g, with the exception of the adrenal gland (700 microg/gland) and paraganglia (100 ng/g). Only the heart showed lower values in Gnt-treated @entity0 . Mean DA levels were also very high in paraganglia (530 ng/g). In the Gnt-treated @entity0 , DA levels fell practically to zero except in the duodenum, mesentery, and adrenal, whereas there were high levels in the paraganglia, which were significantly different from controls. The results suggest that the three @entity4 are contained mainly in noradrenergic sympathetic fibers of muscle, white adipose tissue, heart, liver, pancreas, and spleen. The duodenum and mesentery may have dopaminergic fibers or E- and DA-containing nonneural cells. Hepatic-vagus paraganglia contain all the @entity4 in relatively high amounts in nonneural cells, and Gnt treatment raises DA levels without affecting the other @entity7 .

title: XXXX and @entity1 colocalization with @entity2 in various peripheral tissues: @entity6 effects.

answer: @entity3


abstract: Chemical sympathectomy with @entity6 (Gnt) selectively destroys the postganglionic noradrenergic neurons, whereas dopaminergic fibers and nonneural @entity5 -secreting cells are spared. As a result, the relative proportions of @entity2 (NE), @entity3 (E), and @entity1 (DA) in tissues can be differentially affected. This study was done to show the possible differences in the relative amount of @entity4 in some organs and tissues that might indicate the nature of the secretory cells from which they originate. The contents of NE, E, and DA were assessed in @entity0 neonatally treated with Gnt. Gnt-treated @entity0 showed significantly lower levels of NE (P < 0.01) in all tissues except the adrenal gland and paraganglia. @entity3 was present in all tissues with mean levels below 25 ng/g, with the exception of the adrenal gland (700 microg/gland) and paraganglia (100 ng/g). Only the heart showed lower values in Gnt-treated @entity0 . Mean DA levels were also very high in paraganglia (530 ng/g). In the Gnt-treated @entity0 , DA levels fell practically to zero except in the duodenum, mesentery, and adrenal, whereas there were high levels in the paraganglia, which were significantly different from controls. The results suggest that the three @entity4 are contained mainly in noradrenergic sympathetic fibers of muscle, white adipose tissue, heart, liver, pancreas, and spleen. The duodenum and mesentery may have dopaminergic fibers or E- and DA-containing nonneural cells. Hepatic-vagus paraganglia contain all the @entity4 in relatively high amounts in nonneural cells, and Gnt treatment raises DA levels without affecting the other @entity7 .

title: @entity3 and XXXX colocalization with @entity2 in various peripheral tissues: @entity6 effects.

answer: @entity1


abstract: Chemical sympathectomy with @entity6 (Gnt) selectively destroys the postganglionic noradrenergic neurons, whereas dopaminergic fibers and nonneural @entity5 -secreting cells are spared. As a result, the relative proportions of @entity2 (NE), @entity3 (E), and @entity1 (DA) in tissues can be differentially affected. This study was done to show the possible differences in the relative amount of @entity4 in some organs and tissues that might indicate the nature of the secretory cells from which they originate. The contents of NE, E, and DA were assessed in @entity0 neonatally treated with Gnt. Gnt-treated @entity0 showed significantly lower levels of NE (P < 0.01) in all tissues except the adrenal gland and paraganglia. @entity3 was present in all tissues with mean levels below 25 ng/g, with the exception of the adrenal gland (700 microg/gland) and paraganglia (100 ng/g). Only the heart showed lower values in Gnt-treated @entity0 . Mean DA levels were also very high in paraganglia (530 ng/g). In the Gnt-treated @entity0 , DA levels fell practically to zero except in the duodenum, mesentery, and adrenal, whereas there were high levels in the paraganglia, which were significantly different from controls. The results suggest that the three @entity4 are contained mainly in noradrenergic sympathetic fibers of muscle, white adipose tissue, heart, liver, pancreas, and spleen. The duodenum and mesentery may have dopaminergic fibers or E- and DA-containing nonneural cells. Hepatic-vagus paraganglia contain all the @entity4 in relatively high amounts in nonneural cells, and Gnt treatment raises DA levels without affecting the other @entity7 .

title: @entity3 and @entity1 colocalization with @entity2 in various peripheral tissues: XXXX effects.

answer: @entity6


abstract: OBJECTIVE: To determine the one-year mortality and incidence of @entity3 ( @entity3 ) post-hospital discharge or ED release for @entity0 with @entity5 -associated @entity4 . METHODS: A prospective, observational study of an inception cohort of consecutive @entity0 who presented to one of four municipal hospital EDs with @entity5 -associated @entity4 . @entity0 were followed for one year from the end of the enrollment period. Main outcome parameters were the one-year actuarial survival and the frequency of nonfatal @entity3 . RESULTS: Mortality data were available for all 203 @entity0 at a mean of 408 days. Additional clinical information was available for 185 @entity0 (91%). There were six deaths (one-year actuarial survival 98%; 95% CI, 95-100%); none from @entity3 . Nonfatal @entity3 occurred in two @entity0 (1%; 95% CI, 0-2%). Continued @entity5 use was common (60%; 95% CI, 52-68%) and was associated with recurrent @entity4 (75% vs 31%, p < 0.0001). No @entity3 or @entity2 was reported for @entity0 who claimed to have ceased @entity5 use. CONCLUSIONS: @entity0 who presented with @entity5 -associated @entity4 commonly continued to use @entity5 after discharge. Urgent evaluation of coronary anatomy or cardiac stress tests may not be necessary for @entity0 for whom @entity3 is ruled out and who do not have recurrent potentially @entity1 . The subsequent risk for @entity3 and @entity2 in this group appears to be low. Intervention strategies should emphasize cessation of @entity5 use.

title: XXXX -associated @entity4 : one-year follow-up.

answer: @entity5


abstract: OBJECTIVE: To determine the one-year mortality and incidence of @entity3 ( @entity3 ) post-hospital discharge or ED release for @entity0 with @entity5 -associated @entity4 . METHODS: A prospective, observational study of an inception cohort of consecutive @entity0 who presented to one of four municipal hospital EDs with @entity5 -associated @entity4 . @entity0 were followed for one year from the end of the enrollment period. Main outcome parameters were the one-year actuarial survival and the frequency of nonfatal @entity3 . RESULTS: Mortality data were available for all 203 @entity0 at a mean of 408 days. Additional clinical information was available for 185 @entity0 (91%). There were six deaths (one-year actuarial survival 98%; 95% CI, 95-100%); none from @entity3 . Nonfatal @entity3 occurred in two @entity0 (1%; 95% CI, 0-2%). Continued @entity5 use was common (60%; 95% CI, 52-68%) and was associated with recurrent @entity4 (75% vs 31%, p < 0.0001). No @entity3 or @entity2 was reported for @entity0 who claimed to have ceased @entity5 use. CONCLUSIONS: @entity0 who presented with @entity5 -associated @entity4 commonly continued to use @entity5 after discharge. Urgent evaluation of coronary anatomy or cardiac stress tests may not be necessary for @entity0 for whom @entity3 is ruled out and who do not have recurrent potentially @entity1 . The subsequent risk for @entity3 and @entity2 in this group appears to be low. Intervention strategies should emphasize cessation of @entity5 use.

title: @entity5 -associated XXXX : one-year follow-up.

answer: @entity4


abstract: BACKGROUND: The number of @entity0 with @entity1 is increasing. Lipid treatment guidelines are established for low-density lipoprotein @entity2 (LDL-C) and non-high-density lipoprotein @entity2 (non-HDL-C). The importance of treating HDL-C and @entity5 is gaining recognition. OBJECTIVE: To determine, in @entity0 who had been treated previously with @entity7 40 mg/day, the efficacy, safety, and tolerability of two regimens of a combination of proprietary @entity3 , extended-release core, coated with 40 mg/day @entity7 (NER/S), compared to 80 mg/day @entity7 monotherapy (S80). METHODS: High-risk @entity0 (n = 343) with @entity6 were treated for 24 weeks with NER/S (1000/40 mg/day or 2000/40 mg/day) or S80. RESULTS: Median percentage change from baseline to week 24 in non-HDL-C in either NER/S group was noninferior to S80 (-11.3%, -17.1%, and -10.1%, respectively). Changes in LDL-C were comparable (-8.6%, -11.6%, and -12.7%, respectively). Doubling the dose of @entity7 (S80) did not alter HDL-C, @entity5 , or lipoprotein(a); however, both NER/S doses resulted in significant improvements in all three parameters (+21.9%, -31.8%, and -21.0%, respectively, for NER/S 2000/40 mg/day). The safety of NER/S was consistent with the safety profile of each individual component. Treatment with both doses of NER/S was well tolerated; 59% of @entity0 experienced @entity4 , 78% of @entity4 was mild or moderate in intensity, 49% of those who flushed during dose titration did not flush during weeks 13 to 24, and only 4.6% of @entity0 discontinued because of @entity4 . CONCLUSION: NER/S provides similar reductions in non-HDL-C and LDL-C compared to doubling the @entity7 dose to 80 mg; however, only NER/S resulted in improvements in HDL-C, @entity5 , and lipoprotein(a).

title: Comparison of the efficacy and safety of a combination tablet of niacin extended-release and XXXX with @entity7 80 mg monotherapy: the SEACOAST II (high-dose) study.

answer: @entity7


abstract: BACKGROUND: The number of @entity0 with @entity1 is increasing. Lipid treatment guidelines are established for low-density lipoprotein @entity2 (LDL-C) and non-high-density lipoprotein @entity2 (non-HDL-C). The importance of treating HDL-C and @entity5 is gaining recognition. OBJECTIVE: To determine, in @entity0 who had been treated previously with @entity7 40 mg/day, the efficacy, safety, and tolerability of two regimens of a combination of proprietary @entity3 , extended-release core, coated with 40 mg/day @entity7 (NER/S), compared to 80 mg/day @entity7 monotherapy (S80). METHODS: High-risk @entity0 (n = 343) with @entity6 were treated for 24 weeks with NER/S (1000/40 mg/day or 2000/40 mg/day) or S80. RESULTS: Median percentage change from baseline to week 24 in non-HDL-C in either NER/S group was noninferior to S80 (-11.3%, -17.1%, and -10.1%, respectively). Changes in LDL-C were comparable (-8.6%, -11.6%, and -12.7%, respectively). Doubling the dose of @entity7 (S80) did not alter HDL-C, @entity5 , or lipoprotein(a); however, both NER/S doses resulted in significant improvements in all three parameters (+21.9%, -31.8%, and -21.0%, respectively, for NER/S 2000/40 mg/day). The safety of NER/S was consistent with the safety profile of each individual component. Treatment with both doses of NER/S was well tolerated; 59% of @entity0 experienced @entity4 , 78% of @entity4 was mild or moderate in intensity, 49% of those who flushed during dose titration did not flush during weeks 13 to 24, and only 4.6% of @entity0 discontinued because of @entity4 . CONCLUSION: NER/S provides similar reductions in non-HDL-C and LDL-C compared to doubling the @entity7 dose to 80 mg; however, only NER/S resulted in improvements in HDL-C, @entity5 , and lipoprotein(a).

title: Comparison of the efficacy and safety of a combination tablet of niacin extended-release and @entity7 with XXXX 80 mg monotherapy: the SEACOAST II (high-dose) study.

answer: @entity7


abstract: BACKGROUND: Reduced uteroplacental perfusion, the initiating event in @entity2 , is associated with enhanced @entity5 ( @entity5 ) production which feeds the vasoconstriction of uterine artery. Whether the treatments of @entity2 were effective on @entity5 induced contraction and could reverse placental @entity1 is the question addressed in this study. We investigated the effect of antihypertensive drugs used in @entity2 and of ET receptor antagonists on the contractile response to @entity5 on @entity0 uterine arteries. METHODOLOGY/PRINCIPAL FINDINGS: Experiments were performed, ex vivo, on @entity0 uterine artery samples obtained after hysterectomy. We studied variations in isometric tension of arterial rings in response to the vasoconstrictor @entity5 and evaluated the effects of various vasodilators and ET-receptor antagonists on this response. Among antihypertensive drugs, only @entity11 were effective in blocking and reversing the @entity5 contractile response. Their efficiency, independent of the concentration of @entity5 , was only partial. @entity6 , @entity10 and @entity7 had no effect on @entity5 induced contraction which is mediated by both @entity4 and @entity3 receptors in uterine artery. ET receptors antagonists, @entity8 and @entity9 , slightly reduced the amplitude of the response to @entity5 . Combination of both antagonists was more efficient, but it was not possible to reverse the maximal @entity5 -induced contraction with antagonists used alone or in combination. CONCLUSION: Pharmacological drugs currently used in the context of @entity2 , do not reverse @entity5 induced contraction. Only @entity11 , which partially relax uterine artery previously contracted with @entity5 , might offer interesting perspectives to improve placental perfusion.

title: Endothelin-dependent vasoconstriction in @entity0 uterine artery: application to XXXX .

answer: @entity2


abstract: BACKGROUND: Reduced uteroplacental perfusion, the initiating event in @entity2 , is associated with enhanced @entity5 ( @entity5 ) production which feeds the vasoconstriction of uterine artery. Whether the treatments of @entity2 were effective on @entity5 induced contraction and could reverse placental @entity1 is the question addressed in this study. We investigated the effect of antihypertensive drugs used in @entity2 and of ET receptor antagonists on the contractile response to @entity5 on @entity0 uterine arteries. METHODOLOGY/PRINCIPAL FINDINGS: Experiments were performed, ex vivo, on @entity0 uterine artery samples obtained after hysterectomy. We studied variations in isometric tension of arterial rings in response to the vasoconstrictor @entity5 and evaluated the effects of various vasodilators and ET-receptor antagonists on this response. Among antihypertensive drugs, only @entity11 were effective in blocking and reversing the @entity5 contractile response. Their efficiency, independent of the concentration of @entity5 , was only partial. @entity6 , @entity10 and @entity7 had no effect on @entity5 induced contraction which is mediated by both @entity4 and @entity3 receptors in uterine artery. ET receptors antagonists, @entity8 and @entity9 , slightly reduced the amplitude of the response to @entity5 . Combination of both antagonists was more efficient, but it was not possible to reverse the maximal @entity5 -induced contraction with antagonists used alone or in combination. CONCLUSION: Pharmacological drugs currently used in the context of @entity2 , do not reverse @entity5 induced contraction. Only @entity11 , which partially relax uterine artery previously contracted with @entity5 , might offer interesting perspectives to improve placental perfusion.

title: Endothelin-dependent vasoconstriction in XXXX uterine artery: application to @entity2 .

answer: @entity0


abstract: BACKGROUND: This is the primary report of the large-scale evaluation of @entity12 , an orally administered IIb/IIIa receptor antagonist, a unique trial with respect to the platelet antagonist, protocol design, and inclusion of @entity3 in a significant proportion of @entity0 . METHODS AND RESULTS: @entity0 with @entity7 were randomized to @entity12 30 or 50 mg BID on the basis of age and predicted @entity11 clearance or placebo in addition to @entity4 at a dose ranging from 75 to 325 mg/d at the discretion of the physician-investigator. Follow-up was for up to 2 years. The primary end point was the composite of all-cause mortality, @entity9 , @entity2 , recurrent @entity1 requiring hospitalization, and urgent revascularization. Of 9190 @entity0 enrolled from 23 countries and 690 hospitals, 41% had @entity3 at the time of entry, and 59% had @entity6 . @entity5 occurred in 2.3% of placebo-assigned @entity0 and 3.0% of @entity12 -group @entity0 (hazard ratio 1.33, 95% CI 1.03 to 1.72, P=0.026), and the cause of excess @entity5 was vascular related. There was no significant difference in the primary end point (17.5% compared with 16.4%, respectively; hazard ratio 0.94, 95% CI 0.85 to 1.03, P=0.19). Serious @entity8 was more frequent in the @entity12 group (8.0% compared with 2.8%; P<0.001). Serious @entity8 was more common among @entity0 who received higher doses of @entity4 (>162 mg/d), with or without @entity12 . CONCLUSIONS: @entity12 , an orally administered platelet glycoprotein IIb/IIIa blocker, induced a 33% increase in @entity5 rate, which was vascular in origin and not affected by the type of @entity10 involvement at entry to the trial. Although the dose of @entity4 was not randomly assigned, the finding of increased @entity8 with doses >162 mg/d is noteworthy.

title: Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist XXXX in coronary and @entity3 .

answer: @entity12


abstract: BACKGROUND: This is the primary report of the large-scale evaluation of @entity12 , an orally administered IIb/IIIa receptor antagonist, a unique trial with respect to the platelet antagonist, protocol design, and inclusion of @entity3 in a significant proportion of @entity0 . METHODS AND RESULTS: @entity0 with @entity7 were randomized to @entity12 30 or 50 mg BID on the basis of age and predicted @entity11 clearance or placebo in addition to @entity4 at a dose ranging from 75 to 325 mg/d at the discretion of the physician-investigator. Follow-up was for up to 2 years. The primary end point was the composite of all-cause mortality, @entity9 , @entity2 , recurrent @entity1 requiring hospitalization, and urgent revascularization. Of 9190 @entity0 enrolled from 23 countries and 690 hospitals, 41% had @entity3 at the time of entry, and 59% had @entity6 . @entity5 occurred in 2.3% of placebo-assigned @entity0 and 3.0% of @entity12 -group @entity0 (hazard ratio 1.33, 95% CI 1.03 to 1.72, P=0.026), and the cause of excess @entity5 was vascular related. There was no significant difference in the primary end point (17.5% compared with 16.4%, respectively; hazard ratio 0.94, 95% CI 0.85 to 1.03, P=0.19). Serious @entity8 was more frequent in the @entity12 group (8.0% compared with 2.8%; P<0.001). Serious @entity8 was more common among @entity0 who received higher doses of @entity4 (>162 mg/d), with or without @entity12 . CONCLUSIONS: @entity12 , an orally administered platelet glycoprotein IIb/IIIa blocker, induced a 33% increase in @entity5 rate, which was vascular in origin and not affected by the type of @entity10 involvement at entry to the trial. Although the dose of @entity4 was not randomly assigned, the finding of increased @entity8 with doses >162 mg/d is noteworthy.

title: Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist @entity12 in coronary and XXXX .

answer: @entity3


abstract: OBJECTIVE: To measure @entity3 and @entity4 in long term survivors of @entity0 . DESIGN: Case-control study. SETTING: Follow up of the trial of early detection of @entity0 in the South West Surrey Health District. SUBJECTS: 331 @entity1 with @entity0 aged 50-78, attending mammographic follow up, who had been invited to screening before diagnosis, and 584 controls who had attended the same clinic but did not have @entity0 . The sample included 290 pairs matched by screening attendance pattern and year of birth. MAIN OUTCOME MEASURE: @entity3 and @entity4 scores on the Hospital @entity3 and @entity4 Scale. RESULTS: Significantly fewer symptoms of @entity3 and @entity4 were reported by @entity1 with @entity2 than by controls and significantly fewer had high scores suggesting the presence of psychological morbidity meriting treatment. Among the @entity1 with @entity2 was more common at the first annual follow up than at later visits. Symptom scores were not significantly related to the manner of detection or to the type of initial treatment. Potentially confounding social and personal factors did not account for the differences between @entity1 with @entity2 and controls. CONCLUSION: The prevalence of @entity3 and @entity4 is not increased in long term survivors of @entity0 who are apparently free from disease and is not substantially affected by the manner in which a @entity2 is detected or by the treatment given. In the light of these findings it is difficult to justify large "quality adjustments" to the estimates of recurrence-free years of life saved by screening. Those who counsel @entity1 with @entity0 should be aware that although the initial distress can be severe, meriting psychological treatment, @entity1 do recover their normal ability to enjoy life.

title: Is psychological wellbeing impaired in long-term survivors of XXXX ?

answer: @entity0